



September 30, 2019

British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Ontario Securities Commission

Dear Sirs/Mesdames:

Re: Algernon Pharmaceuticals Inc.

In connection with the final Short Form Prospectus of Algernon Pharmaceuticals Inc. dated September 30, 2019 (the “**Prospectus**”), we consent to the references to our name on page iii and under the headings “Legal Matters” and “Interest of Experts” and consent to the use of our firm’s name and reference to our opinion under the heading “Eligibility for Investment” in the Prospectus.

We have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from our opinion referred to therein or that are within our knowledge as a result of the services that we performed in connection with such opinion.

Yours truly,

(signed) “*McMillan LLP*”